Edison Investment Research: Oncolytics Biotech's Pending Outcome

In a research report published this morning, Edison Investment Research is waiting with bated breath on Oncolytics Biotech's

pending Phase III trial of Reolysin. According to Edison Investment Research, "This study is due to render interim data in mid-2012, which could be the trigger for a major pharmaceutical licensing partnership. Oncolytics has 12 other ongoing clinical trials with Reolysin, including Phase II studies in non-small cell lung, pancreatic, melanoma and ovarian cancers and a Phase I trial in colorectal cancer. Four new Phase II randomised trials sponsored by CTG are due to start in 2012." Oncolytics Biotech closed yesterday at $3.80.